Clinical study of azithromycin

Yoshiro Sawae, Hiroyasu Misumi, Koji Takaki, Toshiyuki Ishimaru, Masaharu Motomura, Yukio Kumagai, Makoto Katsuno, Nobuyuki Shimono, Hiroshi Inoue, Ikuo Sumita, Takatoshi Inoue

Research output: Contribution to journalArticle

Abstract

A clinical study of azithromycin (AZM), a newly developed oral macrolide antibacterial agent, was performed with the following results. AZM at a dose of 250 or 500 mg was administered once a day for 3 days to 22 patients, including 1 case of pharyngolaryngitis, 4 of acute bronchitis and 17 of pneumonia. The clinical effect was evaluated as excellent in 5, good in 13, poor in 1 and undetermined in 3 cases. Adverse reactions thought to have a causal relationship to AZM included coughing, dyspnea and fever in 1 case and a rigidity of anterior chest in 1 case. However, these symptoms disappeared within 1 month after the administration of AZM. Abnormal laboratory values due to drug administration were observed in 3 cases: increased eosinophils in 2, elevated GOT, GPT, ALP, γ-GTP, CRP and ESR in 1.

Original languageEnglish
Pages (from-to)415-419
Number of pages5
JournalJapanese Journal of Chemotherapy
Volume43
DOIs
Publication statusPublished - Jan 1 1995
Externally publishedYes

Fingerprint

Azithromycin
Bronchitis
Macrolides
Guanosine Triphosphate
Eosinophils
Dyspnea
Pneumonia
Fever
Thorax
Anti-Bacterial Agents
Clinical Studies
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Sawae, Y., Misumi, H., Takaki, K., Ishimaru, T., Motomura, M., Kumagai, Y., ... Inoue, T. (1995). Clinical study of azithromycin. Japanese Journal of Chemotherapy, 43, 415-419. https://doi.org/10.11250/chemotherapy1995.43.Supplement6_415

Clinical study of azithromycin. / Sawae, Yoshiro; Misumi, Hiroyasu; Takaki, Koji; Ishimaru, Toshiyuki; Motomura, Masaharu; Kumagai, Yukio; Katsuno, Makoto; Shimono, Nobuyuki; Inoue, Hiroshi; Sumita, Ikuo; Inoue, Takatoshi.

In: Japanese Journal of Chemotherapy, Vol. 43, 01.01.1995, p. 415-419.

Research output: Contribution to journalArticle

Sawae, Y, Misumi, H, Takaki, K, Ishimaru, T, Motomura, M, Kumagai, Y, Katsuno, M, Shimono, N, Inoue, H, Sumita, I & Inoue, T 1995, 'Clinical study of azithromycin', Japanese Journal of Chemotherapy, vol. 43, pp. 415-419. https://doi.org/10.11250/chemotherapy1995.43.Supplement6_415
Sawae Y, Misumi H, Takaki K, Ishimaru T, Motomura M, Kumagai Y et al. Clinical study of azithromycin. Japanese Journal of Chemotherapy. 1995 Jan 1;43:415-419. https://doi.org/10.11250/chemotherapy1995.43.Supplement6_415
Sawae, Yoshiro ; Misumi, Hiroyasu ; Takaki, Koji ; Ishimaru, Toshiyuki ; Motomura, Masaharu ; Kumagai, Yukio ; Katsuno, Makoto ; Shimono, Nobuyuki ; Inoue, Hiroshi ; Sumita, Ikuo ; Inoue, Takatoshi. / Clinical study of azithromycin. In: Japanese Journal of Chemotherapy. 1995 ; Vol. 43. pp. 415-419.
@article{42878dc65a5147bf94667d4ee2edaa66,
title = "Clinical study of azithromycin",
abstract = "A clinical study of azithromycin (AZM), a newly developed oral macrolide antibacterial agent, was performed with the following results. AZM at a dose of 250 or 500 mg was administered once a day for 3 days to 22 patients, including 1 case of pharyngolaryngitis, 4 of acute bronchitis and 17 of pneumonia. The clinical effect was evaluated as excellent in 5, good in 13, poor in 1 and undetermined in 3 cases. Adverse reactions thought to have a causal relationship to AZM included coughing, dyspnea and fever in 1 case and a rigidity of anterior chest in 1 case. However, these symptoms disappeared within 1 month after the administration of AZM. Abnormal laboratory values due to drug administration were observed in 3 cases: increased eosinophils in 2, elevated GOT, GPT, ALP, γ-GTP, CRP and ESR in 1.",
author = "Yoshiro Sawae and Hiroyasu Misumi and Koji Takaki and Toshiyuki Ishimaru and Masaharu Motomura and Yukio Kumagai and Makoto Katsuno and Nobuyuki Shimono and Hiroshi Inoue and Ikuo Sumita and Takatoshi Inoue",
year = "1995",
month = "1",
day = "1",
doi = "10.11250/chemotherapy1995.43.Supplement6_415",
language = "English",
volume = "43",
pages = "415--419",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",

}

TY - JOUR

T1 - Clinical study of azithromycin

AU - Sawae, Yoshiro

AU - Misumi, Hiroyasu

AU - Takaki, Koji

AU - Ishimaru, Toshiyuki

AU - Motomura, Masaharu

AU - Kumagai, Yukio

AU - Katsuno, Makoto

AU - Shimono, Nobuyuki

AU - Inoue, Hiroshi

AU - Sumita, Ikuo

AU - Inoue, Takatoshi

PY - 1995/1/1

Y1 - 1995/1/1

N2 - A clinical study of azithromycin (AZM), a newly developed oral macrolide antibacterial agent, was performed with the following results. AZM at a dose of 250 or 500 mg was administered once a day for 3 days to 22 patients, including 1 case of pharyngolaryngitis, 4 of acute bronchitis and 17 of pneumonia. The clinical effect was evaluated as excellent in 5, good in 13, poor in 1 and undetermined in 3 cases. Adverse reactions thought to have a causal relationship to AZM included coughing, dyspnea and fever in 1 case and a rigidity of anterior chest in 1 case. However, these symptoms disappeared within 1 month after the administration of AZM. Abnormal laboratory values due to drug administration were observed in 3 cases: increased eosinophils in 2, elevated GOT, GPT, ALP, γ-GTP, CRP and ESR in 1.

AB - A clinical study of azithromycin (AZM), a newly developed oral macrolide antibacterial agent, was performed with the following results. AZM at a dose of 250 or 500 mg was administered once a day for 3 days to 22 patients, including 1 case of pharyngolaryngitis, 4 of acute bronchitis and 17 of pneumonia. The clinical effect was evaluated as excellent in 5, good in 13, poor in 1 and undetermined in 3 cases. Adverse reactions thought to have a causal relationship to AZM included coughing, dyspnea and fever in 1 case and a rigidity of anterior chest in 1 case. However, these symptoms disappeared within 1 month after the administration of AZM. Abnormal laboratory values due to drug administration were observed in 3 cases: increased eosinophils in 2, elevated GOT, GPT, ALP, γ-GTP, CRP and ESR in 1.

UR - http://www.scopus.com/inward/record.url?scp=0029591216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029591216&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1995.43.Supplement6_415

DO - 10.11250/chemotherapy1995.43.Supplement6_415

M3 - Article

AN - SCOPUS:0029591216

VL - 43

SP - 415

EP - 419

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

ER -